Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review
International Journal of Chronic Obstructive Pulmonary Disease · 2026
DOI: 10.2147/copd.s629169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2026. Verfasst von Rong Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Health Care Costs, Cost of Illness. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: COPD
Abstract (Originalsprache)
Background
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and healthcare expenditure worldwide. Disease burden and economic value are typically evaluated separately, limiting integrated assessment for value-based healthcare and resource allocation. This review integrated COPD burden-reduction potential with the incremental cost-effectiveness ratio (ICER) to prioritise interventions by health impact and economic value.
Methods
This narrative review was conducted with reference to the Scale for the Assessment of Narrative Review Articles (SANRA). PubMed, Embase, and the Cochrane Library were searched from inception to August 2026 for evidence on COPD burden, healthcare costs, and intervention economic outcomes. Reporting completeness and methodological quality were assessed using CHEERS 2022, the CHEC-list, and AMSTAR 2, as appropriate. Interventions were synthesised within an integrated disability-adjusted life years (DALYs)-ICER framework.
Results
Eighty publications contributed to the synthesis. Acute exacerbations, pulmonary complications, and major comorbidities were the principal drivers of COPD burden and healthcare costs. Smoking cessation and pulmonary rehabilitation showed the most favourable combination of burden-reduction and economic value. Influenza and pneumococcal vaccination showed favourable profiles, although their classification remains provisional because COPD-specific economic evidence is limited. Triple inhaled therapy showed context-dependent economic value across healthcare settings, while long-term azithromycin and long-term oxygen therapy combined with home mechanical ventilation were economically favourable primarily in selected high-risk populations. Ensifentrine and mepolizumab in type 2 COPD demonstrated clinically meaningful benefits but less favourable economic value at the prices evaluated in their source settings. ICS-containing therapy in low-eosinophil, non-exacerbating patients, household air pollution control, and comorbidity-directed interventions could not be formally classified because applicable COPD-specific economic evidence was insufficient.
Conclusion
Integrating burden-reduction potential with ICER-based cost-effectiveness provides a conceptual framework for prioritising COPD interventions by health impact and economic value, while highlighting priorities for COPD-specific economic evaluation and future validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
- Department of Geriatric Internal Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, People's Republic of China.
- Department of Pulmonary and Critical Care Medicine, Enyang District People's Hospital of Bazhong, Bazhong, Sichuan, People's Republic of China.
- Department of Internal Medicine, Linjiang Branch, The Fourth People's Hospital of Nanchong City, Nanchong, Sichuan, People's Republic of China.
ORCID-Profile: Rong Zhang, Lin Chen
Zitieren
APA
Zhang, R., Yang, L., Jing, D., & Chen, L. (2026). Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s629169
Vancouver
Zhang R, Yang L, Jing D, Chen L. Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review. International Journal of Chronic Obstructive Pulmonary Disease. 2026. doi:10.2147/copd.s629169
BibTeX
@article{Zhang2026,
author = {Zhang, Rong and Yang, Lei and Jing, Da and Chen, Lin},
title = {Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2026},
doi = {10.2147/copd.s629169}
}
EUVIMED